Farooqui Zeba, Afsar Mohammad, Rizwan Sana, Khan Aijaz Ahmed, Khan Farah
Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh 202002, U.P., India.
Department of Anatomy, Faculty of Medicine, J. N. Medical College, Aligarh Muslim University, Aligarh 202002, U.P., India.
Toxicol Rep. 2016 Feb 13;3:328-335. doi: 10.1016/j.toxrep.2016.02.004. eCollection 2016.
Cisplatin (CP) is a potent anti-cancer drug widely used against solid tumors. However, it exhibits pronounced adverse effects including hepatotoxicity. Several strategies were attempted to prevent CP hepatotoxicity but were not found suitable for therapeutic application. has been shown to prevent/reduce the progression of certain type of cardiovascular, kidney and liver diseases. Present study investigates whether oil (NSO) can prevent CP induced hepatotoxic effects. Rats were divided into four groups viz. control, CP, NSO and CPNSO. Animals in CPNSO and NSO group were administered NSO (2 ml/kg bwt, orally) with or without single hepatotoxic dose of CP (6 mg/kg bwt, i.p.) respectively. CP hepatotoxicity was recorded by increased serum ALT and AST activities. CP treatment caused oxidant/antioxidant imbalances as reflected by increased lipid peroxidation and decreased enzymatic and non-enzymatic antioxidants. Furthermore, the activities of various carbohydrate metabolism and membrane enzymes were altered by CP treatment. In contrast, NSO administration to CP treated rats, markedly ameliorated the CP elicited deleterious alterations in liver. Histopathological observations showed extensive liver damage in CP treated animals while greatly reduced tissue injury in CPNSO group. In conclusion, NSO appears to protect CP induced hepatotoxicity by improving energy metabolism and strengthening antioxidant defense mechanism.
顺铂(CP)是一种强效抗癌药物,广泛用于治疗实体瘤。然而,它会产生明显的不良反应,包括肝毒性。人们尝试了多种策略来预防顺铂的肝毒性,但都不适合用于治疗。已证明[具体物质未提及]可预防/减轻某些类型的心血管、肾脏和肝脏疾病的进展。本研究调查了[具体物质未提及]油(NSO)是否能预防顺铂诱导的肝毒性作用。将大鼠分为四组,即对照组、顺铂组、NSO组和顺铂+NSO组。顺铂+NSO组和NSO组的动物分别口服NSO(2毫升/千克体重),同时顺铂+NSO组给予单次肝毒性剂量的顺铂(6毫克/千克体重,腹腔注射),NSO组不给予顺铂。通过血清谷丙转氨酶(ALT)和谷草转氨酶(AST)活性升高来记录顺铂的肝毒性。顺铂治疗导致氧化/抗氧化失衡,表现为脂质过氧化增加以及酶促和非酶促抗氧化剂减少。此外,顺铂治疗还改变了各种碳水化合物代谢和膜酶的活性。相比之下,给顺铂处理的大鼠给予NSO,可显著改善顺铂引起的肝脏有害变化。组织病理学观察显示,顺铂处理的动物肝脏有广泛损伤,而顺铂+NSO组的组织损伤大大减轻。总之,NSO似乎通过改善能量代谢和加强抗氧化防御机制来保护顺铂诱导的肝毒性。